Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase I/II, Pilot, Staggered Four-Cohort Safety and Proof-of-Concept Study of ApoGraft in the Prevention of Acute Graft Versus Host Disease (aGvHD)

NCT02828878 is registered in ClinicalTrials.gov with Cellect Biotechnology as lead sponsor.

NCT NCT02828878
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02828878 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase I/II, Pilot, Staggered Four-Cohort Safety and Proof-of-Concept Study of ApoGraft in the Prevention of Acute Graft Versus Host Disease (aGvHD)
Lead sponsor
Cellect Biotechnology
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 31, 2017
Completion date
July 31, 2020
Enrollment
12 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hematological malignancies